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Hepatitis C virus (HCV) infection is a main cause of chronic liver disease, leading to liver cirrhosis and
hepatocellular carcinoma (HCC). The objective of our research was to develop effective agents against
viral replication. We have previously identified the hydrazideehydrazone scaffold as a promising hep-
atitis C virus (HCV) and hepatocelluler inhibitor. Herein we describe the design a number of 20 ,40-
difluoro-4-hydroxy-N'-(arylmethylidene) biphenyl-3-carbohydrazide (3a-t) as anti-HCV and anticancer
agents. Results from evaluation of anti-HCV activity indicated that most of the synthesized hydrazone
derivatives inhibited viral replication in the Huh7/Rep-Feo1b and Huh 7.5-FGR-JCI-Rluc2A reporter
systems. Antiproliferative activities of increasing concentrations of 20 ,40-difluoro-4-hydroxy-N'-(2-
pyridyl methylidene)biphenyl-3-carbohydrazide 3b and diflunisal (2.5e40 mM) were assessed in liver
cancer cell lines (Huh7, HepG2, Hep3B, Mahlavu, FOCUS and SNU-475) with sulforhodamine B assay for
72 h. Compound 3b with 2-pyridinyl group in the hydrazone part exhibited promising cytotoxic activity
against all cell lines with IC50 values of 10, 10.34 16.21 4.74, 9.29 and 8.33 mM for Huh7, HepG2, Hep3B,
Mahlavu, FOCUS and SNU-475 cells, respectively, and produced dramatic cell cycle arrest at SubG1/G0
phase as an indicator of apoptotic cell death induction.
© 2015 Elsevier Masson SAS. All rights reserved.1. Introduction
Hepatitis C virus (HCV) is an enveloped virus that is classified in
the hepacivirus genus of the Flaviviridae family [1]. The virus RNA
genome encodes a polyprotein, which is posttranslationally pro-
cessed by host and virus proteases into 10 mature proteins, of
which 4 are structural proteins (C, E1, E2, and p7) and 6
nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [2].
HCV is a worldwide infectious pathogen that causes chronic liver
diseases, including hepatic fibrosis, hepatic cirrhosis and hepato-
cellular carcinoma (HCC) [3]. Until recently, HCV-infected patients
were treated with a combination of pegylated interferon-a (IFN-a)
and the nucleoside analog ribavirin. However, this therapy hadational Meeting on Pharmacy
23 September, 2014.
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served.limited effectiveness especially in context of patients infected with
HCV genotype 1. Furthermore, treatment with interferon is asso-
ciated with numerous side effects. Recently, new anti-HCV thera-
pies utilizing the direct acting antivirals (DAAs) against the viral
proteins HCV NS3-4A protease and NS5B polymerase have been
approved. These therapy although more promising have compli-
cated dosing regimens limiting patient compliance [4e7]. Further,
the selection of HCV drug resistant variants continues to remain a
concern [8,9]. On the other hand, acute and chronic liver diseases
that are caused by an infectionwith hepatitis-C virus (HCV), such as
hepatocellular carcinoma and liver cirrhosis have received much
attention over the past decade. Recently, HCV is believed to act as
carcinogen by virtue of the increased risk of hepatocellular carci-
noma among persistently infected patients with chronic active
hepatitis. Therefore, it is important to develop new, safer and even
more effective agents against HCV infection and resistance
emergence.
Diflunisal derivatives [10e14] (Fig. 1) have been reported to
possess diverse biological activities such as anticancer, anti-HCV,
Fig. 1. Diflunisal derivatives.
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[15]. In medicinal chemistry, the presence of a hydrazi-
deehydrazone group in compounds, has usually led to the devel-
opment of clinically relevant biological molecules with
antimicrobial, anticancer [16,17] and antiviral properties [18].
Recently, our group reported the synthesis of novel hydrazi-
deehydrazone derivatives and their HCV NS5B inhibition effects
[19] (Fig. 2).
Diflunisal is a difluorophenyl derivative of salicylic acid and a
non-steroidal drug with analgesic, anti-inflammatory and antipy-
retic properties. It is a peripherally-acting non-narcotic analgesic
drug which functions as a prostaglandin synthase inhibitor. In an-
imals, prostaglandins sensitize afferent nerves and potentiate the
action of bradykinin in inducing pain. Since prostaglandins are
known to be among the mediators of pain and inflammation, the
mode of action of diflunisal may be due to a decrease of prosta-
glandins in peripheral tissues.
Herein, we report our ongoing efforts towards development of
more effective anti-HCV agents. We focused our attention on theFig. 2. Hydrazones of anti-HCV activity.hydrazideehydrazone moiety. Thus, a new series of hydrazi-
deehydrazone derivatives were synthesized from diflunisal and
evaluated for their anti-HCV activity in vitro and anticancer activity
against hepatocellular cancer cell lines.
2. Results and discussion
2.1. Chemistry
Methyl 20,40-difluoro-4-hydroxybiphenyl-3-carboxylate [1] was
prepared by the reaction of diflunisal and methanol in the presence
of a few drops of concentrated sulfuric acid. 20,40-Difluoro-4-
hydroxybiphenyl-3-carboxylic acid hydrazide [2] was prepared by
heating hydrazine-hydrate and [1] in methanol [10]. After
condensing hydrazide with substituted aldehydes in ethanol, novel
20,4'-difluoro-4-hydroxy-N'-(arylmethylidene) biphenyl-3-carbo
hydrazide [3a-t] were obtained. The synthesis of novel series of
hydrazideehydrazones 3a-t was performed as outlined in Scheme
1. All synthesized compounds were checked for purity using TLC
and HPLC-UV/DAD and were characterized by their melting points,
1H NMR, 13C NMR and HR-MS spectral data.
The FT-IR spectra of hydrazones showed absorption bands at
1583e1614 cm1 due to C]N groups. Moreover, C]O absorptionScheme 1. The synthetic route for the preparation of the target compounds (3a-t).
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bands associated with other functional groups appeared in the
expected regions. In the 1H NMR spectra of all hydrazones, the
signal representing the azomethine CH protons appeared at
8.41e9.11 ppm, whereas a D2O-exchangeable signal due to NH
amidic proton (eCONHN]CHe) and eOH resonated at
11.78e12.28 ppm. The other protons appeared at the expected
chemical shifts and integral values. 13C NMR spectrum of 3a-t
showed the absence of the C]O signal at d 164.59e165.38 ppm and
eN]CH 144.70e149.32 ppm. Besides, the heteronuclear multiple
bond correlation (HMBC) spectrum of compound 3o also confirmed
the detection of long-range 1He13C couplings. HR-EI (for 3j and 3o)
and DART-MS (for 3d and 3s) confirmed the molecular weights and
empirical formulae of compounds with less than 1 mmu bias be-
tween calculated and experimental m/z values of either molecular
or fragment ions. The major fragmentation pattern involved the
cleavage of the CONHeNH ¼ amide bond m/z 249. The species m/z
232 and m/z177 in compounds (3j, 3o) may results from loss of
eNH2 and subsequent loss of CO in the phenyl ring.2.2. Biological evaluation
2.2.1. Anti-HCV effect of diflunisal hydrazideehydrazones
In order to identify potential anti-HCV agents, we employed two
reporter cell lines, Huh7/Rep-Feo1b and Huh7.5-FGR-JC1-Rluc2A
(Table 1). These cells carry the autonomously replicating HCV RNA
of genotype 1b and 2a in the firefly and Renilla luciferase reporters,
respectively [20e24]. Therefore levels of their respective luciferase
serves as an indicator of HCV RNA replication. The effect of the
compounds on cell viability was investigated in the Huh7.5 parental
cells by the MTS assay and employed to compute 50% cytotoxicity
values (CC50) (Table 1).
The nineteen compounds displayed a wide range of cytotoxicity
in the parental Huh7.5 cells. Among these 3f, 3g, 3i, 3k, 3n, 3o, 3p
and 3t exhibited CC50 < 50 mM, suggesting that these compounds
may be detrimental to cell viability. In contrast, 3c, 3m and 3r with
CC50 > 200 mM, proved to be the least cytotoxic. The remainingTable 1
Anti-HCV activity of diflunisal hydrazideehydrazones (3a-t).
Comp. CC50 (mM)a Huh7.5-FGR-JC1-Rluc2A (% inhibition)b Huh7/R
(Inhibi
3a >50 98 ± 1 91 ± 2
3b >100 90 ± 3 79 ± 3
3c >200 88 ± 10 83 ± 6
3d >50 23 ± 13 33 ± 2
3e >50 95 ± 2 64 ± 2
3f <50 92 ± 5 81 ± 4
3g <50 78 ± 11 90 ± 2
3h >50 74 ± 14 83 ± 2
3i <50 96 ± 3 72 ± 5
3j >100 72 ± 15 69 ± 2
3k <50 95 ± 2 66 ± 3
3l >50 96 ± 2 65 ± 2
3m >200 82 ± 4 77 ± 5
3n <50 95 ± 2 65 ± 1
3o <50 99 ± 1 87 ± 3
3p <50 99 ± 1 86 ± 3
3r >200 70 ± 10 79 ± 3
3s >100 58 ± 11 65 ± 1
3t <50 99 ± 1 92 ± 2
aCC50 values were evaluated in Huh 7.5 parental cells by the MTS assay. Anti-HCV activit
Huh7/Rep-Feo1bc replicon reporter cells. dEC50 values were computed from doseeres
software. Cells treated with equal amounts of DMSO served as control in all experiments
average of three independent experiments with standard deviation. fPercent inhibition o
compound. The data represents an average of three independent measurements. NS5B Rd
of residual background activity. NI, no inhibition; ND, not determined.compounds displayed cytotoxicity in the interim range with com-
pounds 3a, 3d, 3e, 3h, and 3l exhibiting CC50 > 50 mM, while 3b, 3j
and 3s displaying CC50 > 100 mM.
We next screened the compounds at 50 mM concentration for
their anti-HCV activity. With the exception of 3d which exhibited
33% and 23% inhibition against 1b and 2a replicon reporters
respectively, all others displayed 58% inhibition. Notably, all
compounds with the exception of 3g, 3h, 3r and 3a exhibited
higher inhibition of 2a replicons relative to 1b, suggesting higher
antiviral potency of the compounds against HCV genotype 2a.
Compounds exhibiting 70% inhibition against 1b replicon and
CC50  50 mM were further characterized in terms of their EC50
values. This resulted in the identification of 6 compounds 3a, 3b, 3c,
3h, 3m and 3r which met this cut-off criteria and displayed EC50
values ranging between 3.9 and 16.5 mM and selectivity index (SI)
between 3 and 25. Among these, compound 3b, 20,40-difluoro-4-
hydroxy-N'-[(pyridin-2-yl)methylidene]biphenyl-3-
carbohydrazide appeared the most promising with an EC50 of 3.9
and SI > 25.6.
To identify the mechanism of action of these compounds against
HCV, we investigated if the compounds target HCV NS5B. Towards
this end, we screened the compounds in vitro for their ability to
inhibit NS5B RdRp activity. As seen in Table 1, the compounds
displayed no inhibition or 18% inhibition of HCV NS5B, thus
suggesting that the compounds function through a mechanism
other than targeting HCV NS5B.
Further studies are in progress to optimize the structures of
hydrazideehydrazone derivatives with the aim of increasing their
anti-HCV potency.2.2.2. Anticancer activity of compound 3b against liver cancer cell
lines
In order to determine the potential anticancer activity of the
obtained diflunisal hydrazide hydrazone 3b and diflunisal, we
evaluated their cytotoxic activity on liver cancer cell lines (Huh7,
HepG2, Hep3B, Mahlavu, FOCUS and SNU-475) with the sulfo-
rhodamine B assay (2.5e40 mM) for 72 h as described before [25]ep-Feo1b Anti-NS5B Activity (% Inh., 50 mM)f
tion%)c EC50 (mM)d SIe
15.6 ± 1.1 >3.2 17 ± 8
3.9 ± 1.1 >25.6 NI
8.1 ± 3.0 >24.7 8 ± 5
ND ND 7 ± 4
ND ND 8 ± 3
ND ND 9 ± 2
ND ND 7 ± 4





11.8 ± 0.5 >16.9 NI
ND ND NI
ND ND 18 ± 4
ND ND 12 ± 6
16.5 ± 4.2 >6.1 NI
3 ND ND NI
ND ND 14 ± 2
y of the compounds was determined at 50 mM against Huh7.5-FGR-JC1-Rluc2Ab and
ponse curves at 8e10 concentrations of the compounds employing CalcuSyn V2
. eSI: selectivity index represents the ratio of CC50 to EC50. The values shown are an
f HCV NS5B RdRp activity was determined at 50 mM concentration of the indicated
Rp activity in the absence of the inhibitor was taken as 100 percent after subtraction
Table 2
IC50 values of 3b on liver cancer cell lines.
Cell line Diflunisal 3b
IC50 (mM) IC50 (mM)
Huh7 No inhibition 10
HepG2 No inhibition 10.34
Hep3B No inhibition 16.21
Mahlavu 51.7 4.74
Focus 29.8 9.29
SNU-475 No inhibition 8.33
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with IC50 values in micromolar ranges (Table 2). In this study,
diflunisal was included as an experimental control.
Compound 3b, bearing 2-pyridinyl group in the hydrazone core
inhibited cell proliferation with IC50 values between 4.74 and
16.21 mM as shown in Table 2. While Diflunisal showed no inhibi-
tion against Huh7, HepG2, Hep3B, and SNU-475 liver cells, com-
pound 3b by contrast demonstrated anticancer activity against the
same cells with IC50 values 10.0, 10.34, 16.21 and 8.33 mM, respec-
tively. Compound 3b exhibited the highest growth inhibitory ac-
tivity against Mahlavu lines (IC50 ¼ 4.74 mM).2.2.2.1. Effect of diflunisal and compound 3b on the morphology of
Huh 7 and Mahlavu cells. It is known that a cell that is undergoing
apoptosis exhibits nuclear condensation and DNA fragmentation,
which can be detected by staining with Hoechst 33258 and fluo-
rescence microscopy. To examine the nature of cell death induced
upon compound treatment, we next analyzed the changes in cell
morphology with light microscopy. Towards this end, human liver
cancer cells were treated with diflunisal and compound 3b at their
IC50 values for 72 h (Table 2) and compared against DMSO treated
controls. As shown in Fig. 4, compound 3b induced cell death with
diverse morphologies. In Huh7 cells, treatment with 3b at IC50
concentration, resulted in nuclear condensation and DNA frag-
mentation in the cells, which was in parallel with their cell cycle
analysis but no such morphological change were observed upon
diflunisal (Fig. 4).2.2.2.2. Effect of diflunisal and compound 3b on cell cycle arrest in
Huh 7 and Mahlavu cells. In order to investigate the effects of the
compounds on cell cycle, we treated the liver cancer cells withFig. 3. Cytotoxicity induced by the compounds on liver cancer cell lines (Huh7, HepG2,
Hep3B, Mahlavu, FOCUS and SNU-475). The cells were treated with increased con-
centration of the compound (2.5e40 mM) for 72 h. NCI-60 SRB assay was then per-
formed. Absorbance values were obtained and normalized to DMSO control. The
experiment was conducted in triplicate.DMSO or compounds at their IC50 concentrations for 72 h and
stained the cells with propidium iodide. This assay revealed that
compound 3b induced SubG1/Go arrest in Mahlavu cells lines, with
the effect being more prounced in Mahlavu cells (Fig. 5).
2.2.2.3. Apoptosis induction by compound 3b. The changes
observed in fluorescent microscopy together with SubG1 cell cycle
arrest suggested that the compound induced apoptotic cell cycle
arrest. In order to confirm this, the presence of cleaved PARP (an
indicator of apoptitic induction) was investigated in cells treated
with DMSO control, diflunisal or 3b according to IC50 concentra-
tions for 72 h. In Huh7 cells, no cleavage could be observed. On the
other hand, compound 3b caused cleavage of PARP protein indi-
cating that 3b induced apoptosis in Mahlavu liver cancer cell line
(Fig. 6).
3. Conclusion
In this study, a series of 20,40-difluoro-4-hydroxy-N'-(arylme-
thylidene)biphenyl-3-carbohydrazide [3a-t] have been synthesized
and evaluated for their anti-HCV and anticancer activity. The results
revealed increase in cleaved PARP (a marker for apoptosis) in
Mahlavu cells treated with 3b indicating induction of apoptosis. In
Huh7 cells no cleaved fragment was observed. According to FACS
analysis, in both cell lines, treatment with compound 3b resulted in
SubG1 cell cycle arrest. Together, this data indicates that compound
3b may be a promising lead candidate for further optimization and




All reagents and solvents were obtained from commercial sup-
pliers and were used without further purification. Merck silica gel
60 F254 plates were used for analytical TLC. Melting points wee
determined using Schmelzpunktbestimmer SMP II apparatus and
were incorrect. 1H and 13C NMR spectra were recorded on 300 MHz
or 500 MHz Varian UNITY INOVA or HD BRUKER 300 MHz Ultra-
shield TM spectrometer. Elemental analyses were determined by
CHNS-932 (LECO). FT-IR spectra were recorded on a Schimadzu
FTIR-8400S spectrometer. HR-MSmass spectrawere acquired using
a Jeol JMS-700 spectrometer. Purity of the synthesized compounds
has been demonstrated by HPLC analysis using reversed-phase
chromatography. The liquid chromatographic system consists of
an Agilent Technologies 1100 series instrument equipped with a
quaternary solvent delivery system and a model Agilent series
G1315 A photodiode array detector. A Rheodyne syringe loading
sample injector with a 50-mL sample loop was used for the injection
of the analytes. Chromatographic data were collected and pro-
cessed using Agilent Chemstation Plus software. The separation
was performed at ambient temperature using a reverse phase ACE
Fig. 4. Nuclear Hoechst (33258) staining (40) of liver cancer cells treated with IC50 concentrations of the compounds or DMSO control for 72 h.
Fig. 5. Cell cycle distribution of liver cancer cells (Huh7 and Mahlavu) treated with IC50
concentrations of the compounds or DMSO control for 72 h.
S. Şenkardeş et al. / European Journal of Medicinal Chemistry 108 (2016) 301e308 305C18 (4.0  100 mm) column. All experiments were performed in
gradient mode. ACN/H2O system was used as gradient system:
50:50 from 0 to 3 min; 75:25 to 50:50 from 3 to 6 min; 100:0 to
75:25 from 6 to 12 min; the flow rate was 1.0 mL/min with moni-
toring at 254 nm.
4.1.1. Methyl 20,40-difluoro-4-hydroxybiphenyl-3-carboxylate (1)
This was prepared described in the literature [10].
4.1.2. 20,40-difluoro-4-hydroxybiphenyl-3-carboxylic acid hydrazide
(2)
This was prepared described in the literature [10].
4.1.3. General procedure for the synthesized of the compounds
Amixture of appropriate aldehydes and an equimolar amount of
diflunisal hydrazide in ethanol was refluxed for 2 h and novel 20,40-Fig. 6. Western blot results of liver cancer cells treated with IC50 concentrations of the
compounds or DMSO control for 72 h.
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zide [3a-t] were obtained.
4.1.3.1. 20,40-Difluoro-4-hydroxy-N0-[(thiophen-2-yl)methylidene]
biphenyl-3-carbohydrazide (3a). Dark brown solid; Yield: 90%;
HPLC: tR (min.): 8.94; Mp 251 C; FTIR (cm1): 3242 (OeH&NeH),
3072, 3032 (]CeH arom.), 1637 (C]O), 1608 (C]N); 1H NMR
(300 MHz), (DMSO-d6/TMS) d ppm: 7.08 (d, 1H, J ¼ 8.4 Hz, H5), 7.22
(t, 1H, H11), 7.37 (t, 1H, H9), 7.49e7.65 (m, 4H, AreH), 7.72 (d, 1H,
J ¼ 5.1 Hz, H14),7.99 (s, 1H, H2), 8.67 (s, 1H, CH]N), 11.90 (s, 2H,
AreOH&COeNHeN]CH); Anal. Calcd for C18H12F2N2O2S: C, 60.33;
H, 3.38; N, 7.82; S, 8.95; found C, 59.82; H, 3.36; N, 7.79; S, 9.42.
4.1.3.2. 20,40-Difluoro-4-hydroxy-N0-[(pyridin-2-yl)methylidene]
biphenyl-3-carbohydrazide (3b). Light yellow solid; Yield: 80%;
HPLC: tR (min.): 2.76; Mp 241 C; FTIR (cm1): 3254 (OeH&NeH),
3076, 3045 (]CeH arom.), 1639 (C]O), 1614 (C]N); 1H NMR
(300 MHz), (DMSO-d6/TMS) d ppm: 7.10 (d, 1H, J ¼ 8.5 Hz, H5); 7.22
(t, 1H, H11); 7.35e8.65 (m, 8H, AreH); 8.48 (s, 1H, CH]N); 11.85 (s,
1H, AreOH); 12.07 (s, 1H, COeNHeN]CH); Anal. Calcd for
C19H13F2N3O2: C, 64.59; H, 3.71; N, 11.89; found C, 64.32; H, 3.78; N,
11.80.
4.1.3.3. 20,40-Difluoro-4-hydroxy-N0-[(pyridin-3-yl)methylidene]
biphenyl-3-carbohydrazide (3c). Off-white solid; Yield: 88%; HPLC:
tR (min.): 2.39; Mp 277e278 C; FTIR (cm1): 3242 (OeH&NeH),
3041, 3032 (]CeH arom.), 1629 (C]O), 1608 (C]N); 1H NMR
(300 MHz), (DMSO-d6/TMS) d ppm: 7.06 (d, 1H, J ¼ 8.7 Hz, H5); 7.22
(t, 1H, H11); 7.39 (t, 1H, H9); 7.43e8.65 (m, 6H, AreH); 8.02 (s, 1H,
H2); 8.88 (s, 1H, CH]N); 11.92 (s, 1H, AreOH); 12.05 (s, 1H,
COeNHeN]CH); Anal. Calcd for C19H13F2N3O2: C, 64.59; H, 3.71; N,
11.89; found C, 63.75; H, 3.76; N, 11.74.
4.1.3.4. 20,40-Difluoro-4-hydroxy-N0-[(pyridin-4-yl)methylidene]
biphenyl-3-carbohydrazide (3d). Off-white solid; Yield: 86%; HPLC:
tR (min.): 2.51; Mp 261e263 C; FTIR (cm1): 3251 (OeH&NeH),
3036 (]CeH arom.), 1646 (C]O),1608 (C]N); 1H NMR (300MHz),
(DMSO-d6/TMS) d ppm: 7.11 (d, 1H, J ¼ 8.7 Hz, H5); 7.22 (t, 1H, H11);
7.37 (t, 1H, H9); 7.59e7.71 &8.66e8.68 (m, 6H, AreH); 8.02 (s, 1H,
H2); 8.44 (s, 1H, CH]N); 12.12 (s, 2H, AreOH &COeNHeN]CH);
DART-MS; (m/z, Calcd./Found): 354,1048/354,1047
[C19H13F2N3O2þH]þ; 707.2024/707.2009 [2(C19H13F2N3O2)þH]þ;
Anal. Calcd for C19H13F2N3O2: C, 64.59; H, 3.71; N, 11.89; found C,
64.40; H, 4.06; N, 11.67.
4.1.3.5. 20,40-Difluoro-4-hydroxy-N0-[(5-methylthiophen-2-yl)meth-
ylidene]biphenyl-3-carbohydrazide (3e). Light brown solid; Yield:
95%; HPLC: tR (min.): 9.03; Mp 242

C; FTIR (cm1): 3246
(OeH&NeH), 3076, 3047 (]CeH arom.), 1639 (C]O), 1610 (C]N);
1H NMR (300 MHz), (CD3COCD3-d6/TMS) d ppm: 2.52 (s, 3H,
methyl); 6.87 (d, 1H, J ¼ 3.6 Hz, H4, thiophene); 7.08 (d, 1H,
J ¼ 8.7 Hz, H5); 7.22 (t, 1H, H11); 7.30 (d, 1H, J ¼ 3.6 Hz, H3, thio-
phene); 7.38 (t, 1H, H9); 7.56e7.64 (m, 2H, AreH); 7.99 (s, 1H, H2);
8.59 (s, 1H, CH]N); 11.78 (s, 1H, AreOH); 11.99 (s, 1H, COeNHeN]
CH); 13C NMR (150 MHz) (DMSO-d6/TMS) d ppm: 15.86,
104.93,112.47, 116.79,118.02,124.54, 125.50, 126.90, 129.17, 132.16,
132.39, 134.45, 136.93, 143.95, 144.70 (-N]CH), 158.66&160.31
(CeF), 159.11, 161.14&162.77 (CeF), 164.59 (eC]O); Anal. Calcd for
C19H14F2N2O2S: C, 61.28; H, 3.79; N, 7.52; S, 8.61; found C, 60.78; H,
3.66; N, 7.33; S, 9.45.
4.1.3.6. 20,40-Difluoro-4-hydroxy-N0-[(3-bromophenyl)methylidene]
biphenyl-3-carbohydrazide (3f). White solid; Yield: 81%; HPLC: tR
(min.): 4.75; Mp 262

C; FTIR (cm1): 3232 (OeH&NeH), 3047 (]
CeH arom.), 1606 (C]O),1606 (C]N); 1H NMR (300MHz), (DMSO-d6/TMS) d ppm: 7.09 (d, 1H, J ¼ 8.4 Hz, H5); 7.21 (t, 1H, H11); 7.37 (t,
1H, H9); 7.42e7.95 (m, 6H, AreH); 8.01 (s, 1H, H2); 8.41 (s, 1H, CH]
N); 11.94 (2s, 2H, COeNHeN]CH&AreOH). 13C NMR (150 MHz)
(DMSO-d6/TMS) d ppm: 104.92, 112.49, 117.04, 118.08, 122.64,
124.50, 125.61, 126.85, 129.54, 129.77, 131.53, 132.15, 133.30, 134.57,
136.98, 147.49 (eN]CH), 158.65&160.29 (CeF); 158.80,
161.13&162.77 (CeF); 164.79 (eC]O); Anal. Calcd for
C20H13BrF2N2O2: C, 55.70; H, 3.04; N, 6.50; found C, 55.34; H, 2.93;
N, 6.47.
4.1.3.7. 20,40-Difluoro-4-hydroxy-N0-[(2-chlorophenyl)methylidene]
biphenyl-3-carbohydrazide (3g). Light yellow solid; Yield: 86%;
HPLC: tR (min.): 9.65; Mp 269e270 C; FTIR (cm1): 3261
(OeH&NeH), 3078 (]CeH arom.), 1639 (C]O), 1614 (C]N); 1H
NMR (300MHz), (DMSO-d6/TMS) d ppm: 7.06 (d,1H, J¼ 8.4 Hz, H5);
7.22 (t, 1H, H11); 7.39 (t, 1H, H9); 7.33e7.70 (m, 5H, AreH); 8.02 (s,
1H, H2); 8.84 (s, 1H, CH]N); 12.28 (s, 2H, COeNHeN]
CH&AreOH). 13C NMR (75 MHz) (DMSO-d6/TMS) d ppm: 104.90,
112.57, 116.73, 118.28, 124.60, 124.77, 125.05, 127.49, 128.13, 129.27,
130.43, 131.88, 132.17, 133.80, 134.60, 144.91 (eN]CH),
157.91&160.33 (CeF),159.98,161.20&163.44 (CeF), 165.38 (eC]O);
Anal. Calcd for C20H13ClF2N2O2: C, 62.11; H, 3.39; N, 7.24; found C,
61.39; H, 3.23; N, 7.08.
4.1.3.8. 20,40-Difluoro-4-hydroxy-N0-[(2-chloro-6-fluorophenyl)meth-
ylidene]biphenyl-3-carbohydrazide (3h). Light yellow solid; Yield:
78%; HPLC: tR (min.): 9.38; Mp 260 C; FTIR (cm1): 3227
(OeH&NeH), 3080, 3051 (]CeH arom.), 1647 (C]O), 1602 (C]N);
1H NMR (300 MHz), (DMSO-d6/TMS) d ppm: 7.09 (d, 1H, J ¼ 8.4 Hz,
H5); 7.22 (t, 1H, H11); 7.33e7.70 (m, 6H, AreH); 8.01 (s, 1H, H2); 8.69
(s, 1H, CH]N); 11.92 (s, 1H, AreOH); 12.11 (s, 1H, COeNHeN]CH);
Anal. Calcd for C20H12ClF3N2O2: C, 59.35; H, 2.99; N, 6.92; found C,
58.74; H, 2.92; N, 6.75.
4.1.3.9. 20,40-Difluoro-4-hydroxy-N0-[(2,6-dichlorophenyl)methyl-
idene]biphenyl-3-carbohydrazide (3i). Dark yellow solid; Yield:
95%; HPLC: tR (min.): 9.76; Mp 208 C; FTIR (cm1): 3244
(OeH&NeH), 3074, 3032 (]CeH arom.), 1637 (C]O), 1608 (C]N);
1H NMR (300 MHz), (DMSO-d6/TMS) d ppm: 7.10 (d, 1H, J ¼ 8.7 Hz,
H5); 7.22 (t,1H, H11); 7.36 (t, 1H, H9); 7.42e7.67 (m, 5H, AreH); 8.02
(s, 1H, H2); 8.66 (s, 1H, CH]N); 11.87 (s, 1H, AreOH); 12.16 (s, 1H,
COeNHeN]CH); Anal. Calcd for C20H12Cl2F2N2O2: C, 57.03; H,
2.87; N, 6.65; found C, 56.92; H, 2.79; N, 6.62.
4.1.3.10. 20,40-Difluoro-4-hydroxy-N0-[(2,6-difluorophenyl)methyl-
idene]biphenyl-3-carbohydrazide (3j). Off-white solid; Yield: 90%;
HPLC: tR (min.): 8.89; Mp 280 C; FTIR (cm1): 3232 (OeH&NeH),
3046, 3022 (]CeH arom.), 1647 (C]O), 1608 (C]N); 1H NMR
(300 MHz), (DMSO-d6/TMS) d ppm: 7.09 (d, 1H, J ¼ 8.7 Hz, H5);
7.23e7.66 (m, 7H, AreH); 8.01 (s, 1H, H2); 8.61 (s, 1H, CH]N); 12.16
(s, 2H, AreOH&COeNHeN]CH). HRMS (EI, m/z): monoisotopic
mass for C20H12F4N2O2 (Calcd./Found): 388.0834/388.0842; Anal.
Calcd for C20H12F4N2O2: C, 61.86; H, 3.11; N, 7.07; found C, 61.16; H,
2.98; N, 7.07.
4.1.3.11. 20,40-Difluoro-4-hydroxy-N0-[(3,4-dichlorophenyl)methyl-
idene]biphenyl-3-carbohydrazide (3k). Off-white solid; Yield: 82%;
HPLC: tR (min.): 9.53; Mp 258e260 C; FTIR (cm1): 3255
(OeH&NeH), 3076, 3037 (]CeH arom.), 1639 (C]O), 1614 (C]N);
1H NMR (300 MHz), (DMSO-d6/TMS) d ppm: 7.10 (d, 1H, J ¼ 8.7 Hz,
H5); 7.21 (t, 1H, H11); 7.38 (t, 1H, H9); 7.57e8.01 (m, 4H, AreH); 7.75
(s, 1H, H14); 7.78 (s, 1H, H2); 8.43 (s, 1H, CH]N); 11.96 (s, 1H,
AreOH); 12.03 (s, 1H, COeNHeN]CH); Anal. Calcd for
C20H12Cl2F2N2O2: C, 57.03; H, 2.87; N, 6.65; found C, 56.66; H, 3.00;
N, 6.63.
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idene]biphenyl-3-carbohydrazide (3l). Dark brown solid; Yield:
93%; HPLC: tR (min.): 9.28; Mp 196 C; FTIR (cm1): 3228, 3213
(OeH&NeH), 3074 (]CeH arom.), 1635 (C]O), 1606 (C]N); 1H
NMR (300 MHz), (DMSO-d6/TMS) d ppm: 1.25 (t, 3H, methyl); 2.83
(q, 2H, ethyl); 6.89e7.65 (m, 7H, AreH); 8.00 (s, 1H, H2); 8.58 (s, 1H,
CH]N); 11.79 (s, 1H, AreOH); 12.11 (s, 1H, COeNHeN]CH); Anal.
Calcd for C20H16F2N2O2S: C, 62.16; H, 4.17; N, 7.25; S: 8.30; found C,
61.95; H, 4.27; N, 6.90; S, 9.18.
4.1.3.13. 20,40-Difluoro-4-hydroxy-N0-[(4-cyanophenyl)methylidene]
biphenyl-3-carbohydrazide (3m). Light yellow solid; Yield: 82%;
HPLC: tR (min.): 8.23; Mp 284e285 C; FTIR (cm1): 3227
(OeH&NeH), 3066, 3022 (]CeH arom.), 1633 (C]O), 1612 (C]N);
1H NMR (300 MHz), (DMSO-d6/TMS) d ppm: 7.11 (d, 1H, J ¼ 8.4 Hz,
H5); 7.22 (t, 1H, H11); 7.39 (t, 1H, H9); 7.57e7.94 (m, 6H, AreH); 8.01
(s, 1H, H2); 8.52 (s, 1H, CH]N); 12.06 (s, 2H, COeNHeN]
CH&AreOH). 13C NMR (75 MHz) (DMSO-d6/TMS) d ppm: 104.95,
112.62, 117.16, 118.01, 119.10, 124.44 (CN), 124.62, 125.64, 128.25,
129.65, 132.10, 133.63, 134.63, 139.02, 147.20 (eN]CH);
157.93&160.26 (CeF); 159.74, 161.21&163.94 (C-10); 164.80 (-C]
O); Anal. Calcd for C21H13F2N3O2: C, 66.84; H, 3.47; N,11.14; found C,
66.30; H, 3.44; N, 11.05.
4.1.3.14. 20,40-Difluoro-4-hydroxy-N0-[(2,2-difluoro-1,3-benzodioxol-
5-yl)methylidene] biphenyl-3-carbohydrazide (3n). White solid;
Yield: 82%; HPLC: tR (min.): 9.64; Mp 244e245 C; FTIR (cm1):
3244 (OeH&NeH), 3080, 3024 (]CeH arom.), 1641 (C]O), 1583
(C]N); 1H NMR (300 MHz), (DMSO-d6/TMS) d ppm: 7.11 (d, 1H,
J ¼ 8.5 Hz, H5); 7.22 (t, 1H, H11); 7.38 (t, 1H, H9); 7.51e7.65 (m, 5H,
AreH); 8.02 (s, 1H, H2); 8.47 (s, 1H, CH]N); 11.94 (s, 2H,
COeNHeN]CH&AreOH). 13C NMR (150 MHz) (DMSO-d6/TMS)
d ppm: 104.93, 108.04, 110.95, 112.41, 116.95, 118.07, 124.51, 125.31,
125.45, 129.97& 131.95&133.31 (CeF); 124.55, 131.71, 132.14,
134.52, 143.83, 144.42, 147.33 (eN]CH); 158.66&160.30 (CeF);
159.10, 161.12. 162.80 (CeF), 164.79 (eC]O); Anal. Calcd for
C21H12F4N2O4: C, 58.34; H, 2.80; N, 6.48; found C, 57.86; H, 2.73; N,
6.37.
4.1.3.15. 20,40-Difluoro-4-hydroxy-N0-{[3-(trifluoromethyl)methyl-
idene}biphenyl-3-carbohydrazide (3o). White solid; Yield: 92%;
HPLC: tR (min.): 9.72; Mp 221 C; FTIR (cm1): 3257 (OeH&NeH),
3047 (]CeH arom.), 1641 (C]O),1608 (C]N); 1H NMR (500MHz),
(DMSO-d6/TMS) d ppm: 7.09 (d, 1H, J ¼ 8.7 Hz, H5); 7.20 (t, 1H, H11);
7.35 (t, 1H, H9); 7.57e8.04 (m, 6H, AreH); 8.08 (s, 1H, H2); 8.54 (s,
1H, CH]N); 12.02 (s, 2H, COeNHeN]CH&AreOH) (exchangeable
with D2O). 13C NMR (125 MHz) (DMSO-d6/TMS) d ppm: 105.16,
112.78, 117.34, 118.25, 121.45&123.62&125.78&127.95 (eCF3);
123.87, 124.76, 125.86, 127.23, 129.83, 130.28, 130.79, 131.89, 132.38,
134.79, 135.97, 147.71 (eN]CH); 158.74&160.71 (CeF), 159.02,
161.22, 163.18 (CeF), 165.05 (eC]O). HRMS (EI,m/z): monoisotopic
mass for C21H13F5N2O2 (Calcd./Found): 420.0897/420.0894; Anal.
Calcd for C21H13F5N2O2: C, 60.01; H, 3.12; N, 6.66; found C, 59.69; H,
3.45; N, 6.57.
4.1.3.16. 20,40-Difluoro-4-hydroxy-N0-{[4-(trifluoromethyl)phenyl]
methylidene}biphenyl-3-carbohydrazide (3p). Yellow solid; Yield:
81%; HPLC: tR (min.): 9.69; Mp 260 C; FTIR (cm1): 3261
(OeH&NeH), 3074, 3049 (]CeH arom.), 1633 (C]O), 1616 (C]N);
1H NMR (300 MHz), (DMSO-d6/TMS) d ppm: 7.10 (d, 1H, J ¼ 8.4 Hz,
H5); 7.22 (t, 1H, H11); 7.39 (t, 1H, H9); 7.57e7.97 (m, 6H, AreH); 8.02
(s, 1H, H2); 8.54 (s, 1H, CH]N); 11.91 (s, 1H, AreOH) 12.04 (s, 1H,
COeNHeN]CH); Anal. Calcd for C21H13F5N2O2: C, 60.01; H, 3.12; N,
6.66; found C, 59.58; H, 3.01; N, 6.64.4.1.3.17. 20,40-Difluoro-4-hydroxy-N0-[(napthalen-1-yl)methylidene]
biphenyl-3-carbohydrazide (3r). Yellow solid; Yield: 80%; HPLC: tR
(min.): 9.41; Mp 266e268 C; FTIR (cm1): 3265 (OeH&NeH),
3078, 3047 (]CeH arom.), 1637 (C]O), 1612 (C]N); 1H NMR
(300 MHz), (DMSO-d6/TMS) d ppm: 7.13 (d, 1H, J ¼ 8.4 Hz, H5); 7.24
(t, 1H, H11); 7.41 (t, 1H, H9); 7.60e8.95 (m, 10H, AreH); 9.11 (s, 1H,
CH]N); 12.01 (s, 2H, AreOH&COeNHeN]CH); Anal. Calcd for
C24H16F2N2O2: C, 71.64; H, 4.01; N, 6.96; found C, 71.34; H, 4.07; N,
6.98.
4.1.3.18. 20,40-Difluoro-4-hydroxy-N0-[(napthalen-2-yl)methylidene]
biphenyl-3-carbohydrazide (3s). Light yellow solid; Yield: 89%;
HPLC: tR (min.): 9.88; Mp 279 C; FTIR (cm1): 3244 (OeH&NeH),
3047, 3039 (]CeH arom.), 1651 (C]O), 1606 (C]N); 1H NMR
(300 MHz), (DMSO-d6/TMS) d ppm: 7.10 (d, 1H, J ¼ 8.4 Hz, H5); 7.22
(t, 1H, H11); 7.38 (t, 1H, H9); 7.57e8.05 (m, 9H, AreH); 8.25 (s, 1H,
H2); 8.61 (s, 1H, CH]N); 11.95 (s, 1H, AreOH&COeNHeN]CH). 13C
NMR (150 MHz) (DMSO-d6/TMS) d ppm: 104.93, 112.49, 116.99,
118.06, 123.19, 124.52, 127.29, 127.76, 128.27, 128.86, 129.04, 129.41,
129.54, 132.15, 132.21, 132.27, 133.27, 134.32, 134.54, 149.32 (-N]
CH), 158.67&160.14, 159.04, 160.31&162.77, 164.87 (-C]O). DART-
MS; (m/z, Calcd/Found): 403.1253/403.1258 [C24H16F2N2O2þH]þ;
805.2432/805.2445 [2(C24H16F2N2O2)þH]þ; Anal. Calcd for
C24H16F2N2O2: C, 71.64; H, 4.01; N, 6.96; found C, 71.64; H, 3.82; N,
6.86.
4.1.3.19. 20,40-Difluoro-4-hydroxy-N0-[(3-phenoxyphenyl)methyl-
idene]biphenyl-3-carbohydrazide (3t). Yellow solid; Yield: 85%;
HPLC: tR (min.): 9.21; Mp 198 C; FTIR (cm1): 3257 (OeH&NeH),
3064, 3020 (]CeH arom.), 1635 (C]O), 1614 (C]N); 1H NMR
(300MHz), (DMSO-d6/TMS) d ppm: 6.98e7.64 (m,14H, AreH); 8.01
(s, 1H, H2); 8.44 (s, 1H, CH]N); 11.82 (s, 1H, AreOH); 11.94 (s, 1H,
COeNHeN]CH); Anal. Calcd for C26H18F2N2O3: C, 70.26; H, 4.13; N,
6.32; found C, 69.90; H, 4.13; N, 6.32.
4.2. Biological studies
4.2.1. Cell culture
Huh7/Rep-Feo1b and Huh7.5-FGR-JC1-Rluc2A replicon reporter
cells were cultured in Dulbecco's modified Eagle's medium
(DMEM) containing 10% fetal calf serum, 5% antibiotic and 0.5 mg/
mL G418. All cells were cultured at 37 C and 5% CO2.
4.2.2. HCV replicon based luciferase reporter assays
The Huh7/Rep-Feo1b and Huh7.5-FGR-JC1-Rluc2A replicon re-
porter cells have been described previously [20,21]. To evaluate the
anti-HCV activity of the compounds, HCV replicon reporter cells
were seeded in 96 well plate at a confluence of 1  104 cells/well.
Eight hours post seeding, the cells were treated with the individual
compounds (100 mM/well) or equivalent amounts of DMSO for 42 h.
Cell viability was measured in the parental Huh7.5 cells by the
colorimetric MTS assay employing the CellTiter 96AQueous One
Solution assay reagent (Promega, USA). The anti-HCV activity of the
compounds was evaluated as the relative levels of the luciferase
signals in compound treated cells versus DMSO controls.
4.2.3. NS5B inhibition assay
The biological activity of the compounds against NS5B poly-
merase were evaluated in a reaction buffer containing 20 mM
TriseHCl (pH 7.0), 100 mM NaCl, 100 mM sodium glutamate,
0.1 mM DTT, 0.01% BSA, 0.01% Tween-20, 5% glycerol, 20 U/mL of
RNase Out, 0.25 mMof polyrA/U12, 25 mMUTP, 2 mCi [alpha-32P]UTP,
300 ng of NS5BCD21and 1.0 mM MnCl2 with or without inhibitors
(100 mM) in a total volume of 25 mL for 1 h at 30 C as previously
described [26,27]. Reactions were terminated by the addition of
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rophosphate. Reaction products were precipitated on GF-B filters
and quantified on a liquid scintillation counter. NS5B activity in the
presence of DMSO control was set at 100% and that in the presence
of the compounds was determined relative to this control.
4.2.4. Anticancer activity against hepatocelluler cell lines
4.2.4.1. Cell culture. Human liver cancer cell lines were grown in
the standard growth medium (2 mM L-glutamine, 0.1 mM nones-
sential amino acids, 100 units/mL penicillin, 100 lg/mL strepto-
mycin, 10% FCS in DMEM (Gibco, Invitrogen) or RPMI (Gibco,
Invitrogen) and incubated at 37 C under 5% CO2.
4.2.4.2. Sulforhodamine B (SRB) assay for cytotoxicity screening.
Human liver cancer cells were cultured in 96-well plates
(1000e3000 cell/well) and for 24 h. They were treated with
increasing concentrations of the compounds (2.5e40 mM). Cell
were washed with 1 PBS (CaCl2-, MgCl2-free) (Gibco, Invitrogen)
at the end of 72 h incubation period. Fixation was performed using
10% (v/v) trichloroacetic acid (MERCK). Finally, 0.4% (m/v) of sul-
forhodamine (SigmaeAldrich) in 1% acetic acid solution was added
to each well for staining process. The bound sulforhodamine B was
then solubilized using 10 mM Tris-base. The absorbance values
were obtained at 515 nm.
4.2.4.3. Hoechst stain. Human liver cancer cells (Huh7 and Mah-
lavu) were inoculated in 6-well plates for 24 h. The cells were
treated with IC50 concentrations of the compounds for 72 h.
Hoescht 33258 (SigmaeAldrich) staining was used to determine
nuclear condensation. Cells were fixed with 1 mL of cold methanol
and the samples were incubated with 3 lg/mL of Hoescht, and
examined under fluorescent microscopy (40).
4.2.4.4. Western blotting. Human liver cancer cells were cultured in
100 mm culture dish. 24 h later, growth mediumwas replaced and
cells were treated with IC50 concentrations of the compounds or
DMSO controls. At the end of 72 h incubation, samples were scra-
ped and collected for western blot analysis. Anti-PARP antibody
(Cell Signaling, 9532) and anti-b-actin antibody (Sigma, 5441) were
used as primary antibodies. Anti-rabbit (6154) and anti-mouse
(0168) secondary antibodies were used.
4.2.4.5. Cell cycle analysis. Cells were treated with IC50 concentra-
tions of the compounds or 72 h. Then samples were stained with
propidium iodidewhich binds to DNA and analyzedwithMUSE Cell
Cycle analyzer kit.
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[18] S. Rollas, Ş.G. Küçükgüzel, Molecules 12 (2007) 1910e1939.
[19] S. Aydın, N. Kaushik-Basu, P. Arora, A. Basu, D.B. Nichols, T.T. Talele,
Ş.G. Küçükgüzel, Marmara Pharm. J. 17 (2013) 26e34.
[20] K. Kim, K.H. Kim, H.Y. Kim, H.K. Cho, N. Sakamoto, J. Cheong, FEBS Lett. 584
(2010) 707e712.
[21] D.B. Nichols, G. Fournet, K.R. Gurukumar, A. Basu, J.C. Lee, N. Sakamoto,
F. Kozielski, I. Musmuca, B. Joseph, R. Ragno, N. Kaushik-Basu, Eur. J. Med.
Chem. 49 (2012) 191e199.
[22] Y. Sekine-Osajima, N. Sakamoto, M. Nakagawa, Y. Itsui, M. Tasaka,
Y. Nishimura-Sakurai, C.H. Chen, G. Suda, K. Mishima, Y. Onuki, M. Yamamoto,
S. Maekawa, N. Enomoto, T. Kanai, K. Tsuchiya, M. Watanabe, Hepatol. Res. Off.
J. Jpn. Soc. Hepatol. 39 (2009) 60e69.
[23] I. Kucukguzel, G. Satilmis, K.R. Gurukumar, A. Basu, E. Tatar, D.B. Nichols,
T.T. Talele, N. Kaushik-Basu, Eur. J. Med. Chem. 69 (2013) 931e941.
[24] I.A. Andreev, D. Manvar, M.L. Barreca, D.S. Belov, A. Basu, N.L. Sweeney,
N.K. Ratmanova, E.R. Lukyanenko, G. Manfroni, V. Cecchetti, D.N. Frick,
A. Altieri, N. Kaushik-Basu, A.V. Kurkin, Eur. J. Med. Chem. 96 (2015) 250e258.
[25] P. Çıkla-Süzgün, N. Kaushik-Basu, A. Basu, P. Arora, T.T. Talele, I. Durmaz,
R. Cetin-Atalay, S.G. Kucukguzel, J. Enzyme Inhib. Med. Chem. 30 (2015)
778e785.
[26] L. Tomei, R.L. Vitale, I. Incitti, S. Serafini, S. Altamura, A. Vitelli, R. De Francesco,
J. Gen. Virol. 81 (2000) 759e767.
[27] T. Kashiwagi, K. Hara, M. Kohara, K. Kohara, J. Iwahashi, N. Hamada,
H. Yoshino, T. Toyoda, Biochem. Biophys. Res. Commun. 290 (2002)
1188e1194.
